^
Association details:
| Biomarker: | KIT D816V |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KIT exon 8 mutations associated with core-binding factor (CBF)–acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
Excerpt:
Maximal stimulation of KIT-WT and exon 8 mutants in terms of proliferation could be fully reverted by the KIT inhibitor imatinib (Table 2) in contrast to the D816V mutant, which was resistant as described previously.
DOI:
https://doi.org/10.1182/blood-2004-06-2068
